Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
The Differences in Prescription of Transplantation
We use MRD in our practice. Any patient that's MRD positive after consolidation, we're considering them for transplant. And then high risk patients, so our KMT2As or MLLs, those patients we've been taking a transplant. Basically, high risk cytogenetic or molecular features, things like achros, deletions, etc., plus poor response to therapy, plus potentially traditional risk factors. So what did we see in this trial in this UK ALL 2014 study? What they found was the really high induction death rates with early PEG.
Transcript
Play full episode
